| Project/Area Number |
17590808
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Kinki University |
|---|
Principal Investigator |
SATOH Taroh Kinki University, School of Medicine Depertment of Medicine Division of Medical Oncology, Assistant Professor (40368303)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAKAGAWA Kazuhiko Kinki University, School of Medicine, Professor (40298964)
FUKUOKA Masahiro Kinki University, School of Medicine, Professor (20047202)
田村 研治 近畿大学, 医学部附属病院, 講師 (60340783)
津谷 あす香 近畿大学, 医学部附属病院, 助手 (90351600)
|
|---|
| Project Period (FY) |
2005 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥3,270,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥270,000)
Fiscal Year 2007: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2006: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2005: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Keywords | EGFR / gefitinib / NSCLC / meloxicum / PEG2. / PGI2 |
|---|
| Research Abstract |
It has been said that inhibitor of EGFR, gefitinib is effective for reurrent pretreated Non Small Cell Lung Cancer (NSCLC). Overexpression of COX-II is highly related to prognosis for NSCLC. There are some synergism in anticancer agents and COX-II inhibitors. Expression of COX-II is related to EGFR. Based on these results we conducted phase II clinical trial for NSCLC to investigate effectiveness of combination therapy with gefitinib and COX-II inhibitor, meloxicum.
【Objectives】 The objective of this study is to evaluate the response rate and safety of combination therapy with gefitinib and meloxicum.
【Patients】 NSCLC patients diagnosed with histology, good performance status(0-2), within 2 regimens of prior treatment and having measurable lesions were eligible for this study.
【Methods】 All patients were treated with gefitinib 250mg/meloxicum 10 mg once a day from day 1 until PD.
【Results】 Twenty three patients were enrolled. Backgrounds for these patients were as follows; male/female: 10/13、histology; adenocarcinoma/squamous cell carcinoma/NSCLC: 18/3/2、PS (performance status) 0/1/2:3/18/2, clinical stage; III/IV:5/18、MST: 210days. We did not see any correlation in expression level of EGFR. Phosphorelated EGFR, expression of COX-II in histopathopogical staining. There were no relation in plasma level of COX-2, PEG2, PGI2 and other prostagrandines.
|
